Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Saroja Pharma Industries India Ltd

Chemicals & Petrochemicals | Small Cap

Saroja Pharma Industries India Ltd Health Insights
Health Score : 7.47Health Score : 7.47

Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Saroja Pharma Industries India Ltd Health Insights
Health Score : 7.47Health Score : 7.47

Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

11.08

Undervalued

Industry Median

22.59

Undervalued
Undervalued

Small Cap Median

21.70

Undervalued

P/E RATIO

13.67

P/B RATIO

0.87

Highly Undervalued

Industry Median

1.76

Highly Undervalued
Undervalued

Small Cap Median

1.77

Undervalued

P/S RATIO

0.26

Highly Undervalued

Industry Median

0.89

Highly Undervalued
Highly Undervalued

Small Cap Median

0.88

Highly Undervalued

Others

Neutral

PEG RATIO

0.00

Neutral
Undervalued

EV/EBITDA RATIO

4.71

Undervalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹35 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 8.00

The company demonstrates strong growth in revenue and assets, but earnings per share growth is a concern. High growth rates in revenue and assets indicate successful expansion, while negative EPS growth suggests challenges in translating revenue into profits. This mixed performance requires attention to improve profitability alongside growth.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
PoorEarnings Per Share (EPS) GrowthPoor
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate51.75-9.78-18.9732.1130.73
Operating Profit Growth Rate61.5429.52-5.888.5937.05
Earnings Per Share (EPS) Growth-93.08-92.85-39.3416.8957.42
Asset Growth Rate88.6937.5924.5148.855.56
Net Income Growth Rate56.16-7.02-16.9817.0557.28
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.60

The company's financial metrics present a mixed picture. While capital expenditures are well-managed, adjusted and cash earnings per share are low, and the book value per share is also a concern. The absence of dividends may deter some investors. Overall, these factors indicate areas needing improvement to enhance financial performance and investor appeal.

WeakAdjusted Earnings Per Share (Adjusted EPS)Weak
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)573.662.22.574.05
Cash Earnings Per Share (Cash EPS)59.53.92.422.854.33
Book Value Per Share201.517.5536.639.243.22
Dividend Per Share (DPS)00000
Capital Expenditures (CapEx)0.33.70.40.111.5
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 9.80

The company exhibits strong profitability, with high gross profit margins, ROCE, ROE, and ROA, indicating efficient operations and effective use of capital. This robust profitability enhances the company's financial stability and attractiveness to investors. This indicates that company is very profitable and is using its capital very efficiently.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
GoodReturn on Assets (ROA)Good
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin3.695.286.074.975.27
Return on Capital Employed (ROCE)33.5522.0914.9312.5713.02
Return on Equity (ROE)28.2920.836.016.579.37
Return on Assets (ROA)13.5412.759.637.039.13
Operating Margin3.775.426.295.175.42
Net Margin2.052.112.161.922.31
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 6.67

The company demonstrates strong efficiency in managing fixed assets and inventory, but struggles with receivables management. High turnover ratios for fixed assets and inventory indicate effective utilization, while longer receivable days suggest potential issues in collecting payments promptly. This mixed performance highlights areas for improvement in working capital management.

ExcellentFixed Asset Turnover RatioExcellent
ExcellentInventory Turnover RatioExcellent
WeakReceivables Turnover RatioWeak
ExcellentDays Sales in Inventory RatioExcellent
PoorReceivable DaysPoor
WeakCapital Turnover RatioWeak
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio163.6222.6116.221.4132.22
Inventory Turnover Ratio94.8321.9117.89204.24138.63
Receivables Turnover Ratio5.2542.972.513.2
Days Sales in Inventory Ratio3.8516.6620.41.792.63
Receivable Days69.5291.25122.9145.42114.06
Capital Turnover Ratio9.716.362.363.152.85
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 4.40

The company's coverage ratios suggest a limited ability to cover its interest expenses and equity dividends. While the interest coverage ratio is adequate, the lack of equity dividend coverage is a concern. This situation may limit the company's financial flexibility and attractiveness to investors.

AverageInterest Coverage RatioAverage
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio2.962.131.832.032.53
Equity Dividend Coverage Ratio
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company exhibits a strong solvency position, indicating a solid financial structure with low debt levels relative to equity and assets. This provides a stable foundation for future growth and reduces the risk of financial distress. This suggests a financially stable company capable of meeting its long-term obligations.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.30.350.150.080.3
Debt to Equity Ratio0.430.540.180.090.43
Equity Ratio0.70.650.850.920.7
Debt To Asset Ratio0.110.130.10.030.18
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 4.94

The company's liquidity position indicates challenges in meeting its short-term obligations. While the quick ratio suggests some ability to cover immediate liabilities, the low cash ratio raises concerns about reliance on converting other assets to cash. This mixed performance requires careful monitoring to ensure the company can manage its current liabilities effectively.

WeakCurrent RatioWeak
GoodQuick RatioGood
PoorCash RatioPoor
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.551.281.91.251.09
Quick Ratio1.50.991.861.241.04
Cash Ratio0.030.030.030.010.02
Operating Cash Flow Ratio-0.380.160.110.050.44
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 5 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Saroja Pharma Industries India Ltd7.4713.67Neutral3.814.021.62
2Sanginita Chemicals Ltd7.1762.58Undervalued-6.00-3.74-10.00
3Yasons Chemex Care Ltd5.9122.35Neutral-0.590.490.94
4Vadivarhe Speciality Chemicals Ltd4.07-3.66Highly Undervalued-6.42-7.25-9.27
5Omkar Speciality Chemicals Ltd3.630.23Highly Undervalued101.00-6.4237.00
Management Assessment Summary
OrangeBalanced Management

The management effectiveness of Saroja Pharma Industries India Ltd shows a mixed performance. The company has demonstrated revenue expansion but there are concerns regarding declining ROCE and increasing Debt. The high promoter holding indicates confidence of the promoters in the business.

Category Metric Value Assessment
PROS Promoter Holding 73.02% High promoter holding indicates promoter confidence
CONS ROCE (Mar 2025) 12.57% Declining ROCE indicates decreasing efficiency in capital utilization
CONS Borrowings (Mar 2025) 9.46 Cr Increasing debt can increase financial risk
AverageFinancial Performance & GrowthAverage
WeakCapital Efficiency & ReturnsWeak
AverageFinancial Health & PrudenceAverage
GoodShareholding & Ownership StructureGood
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

Saroja Pharma Industries India Ltd. faces moderate risk due to fluctuations in sales growth, and increasing Debt. While the promoter holding is stable, the declining ROCE and increasing Debt raise concerns about long-term financial health and operational efficiency.

PoorSegment performance volatilityPoor
AverageAccounting quality red flagsAverage
AverageForeign exchange or interest rate exposureAverage
AverageRegulatory compliance cost trendsAverage
01.

Segment performance volatility

02.

Accounting quality red flags

03.

Foreign exchange or interest rate exposure

04.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe